Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Awards Honor Companies Creating Breakthroughs in Pharmaceutical and Life Sciences Industry Through the Use of Microsoft Technology PHILADELPHIA, June 20 /PRNewswire-FirstCall/ -- Microsoft Corp...
Major Milestone in Broadening the Ciclesonide Product Platform FLORHAM PARK, N.J., March 7 /PRNewswire-FirstCall/ -- ALTANA Pharma US, Inc. announced today that the U.S. Food and Drug...
Nanophase Technologies Announces Exclusive Partnership With and $10 Million Investment by Altana Chemie AG ROMEOVILLE, Ill., March 25 /PRNewswire-FirstCall/ -- Nanophase Technologies Corporation...
Saturday test ignore Pimswire
TEST ONLY TEST ONLY TEST ONLY TEST ONLY Unaudited accounts Unaudited accounts Audited accounts for the six months for the six months for the year Notes ended 30 June 2002 ended 30 June 2001 ended...
THIS IS A PIMSWIRE TEST MESSAGE 6th August, 2010 TEST COMPANY HOLDINGS LIMITED PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2010 Chairman's Statement Although the Chinese economy experienced...
THIS IS A PIMSWIRE TEST MESSAGE 6th August, 2010 TEST COMPANY HOLDINGS LIMITED PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2010 Chairman's Statement Although the Chinese economy experienced...
Test
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.04 | 0.15923566879 | 25.12 | 25.1802 | 25.04 | 8566 | 25.14559026 | SP |
| 4 | 0.03 | 0.119379228014 | 25.13 | 25.22 | 25.01 | 8808 | 25.12409279 | SP |
| 12 | -0.01 | -0.0397298371077 | 25.17 | 25.22 | 25 | 8095 | 25.09617048 | SP |
| 26 | -0.05 | -0.198333994447 | 25.21 | 25.28 | 24.95 | 6995 | 25.08984672 | SP |
| 52 | 0.06 | 0.239043824701 | 25.1 | 25.28 | 24.95 | 7522 | 25.09162319 | SP |
| 156 | 0.12 | 0.479233226837 | 25.04 | 25.28 | 24.03 | 3606 | 24.97325751 | SP |
| 260 | 0.1 | 0.399042298484 | 25.06 | 25.4 | 24.03 | 3479 | 24.98159302 | SP |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
